A Conversation with PharmAla Biotech CEO Nick Kadysh on What the Trump FDA and AI mean for the Biotech Landscape

In this episode of the WTR Biotech Spotlight, Water Tower Research’s Tim Gerdeman is joined by Nick Kadysh, Founding CEO and President of Toronto-headquartered Life Sciences company, PharmAla Biotech (CSE: MDMA; OTCQB: MDXXF),and WTR Senior Analyst Robert Sassoon for an insightful discussion on arguably the two main topics that are currently concentrating the minds of  biotech industry folk: The implications of the Trump Administration's FDA reforms and  AI's role in reshaping the industry.With over a decade of experience as a Public Affairs and Regulatory expert, Nick Kadysh founded PharmAla in 2020 to focus on the manufacturing and development of MDMA and MDMA-related molecules. Kadysh is also a prominent spokesman for the deployment of AI in drug discovery,